Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine
Objective: To evaluate the steady state pharmacokinetics of nevirapine (NVP) in HIV-infected children receiving a fixed-dose combination of stavudine, lamivudine and NVP. Methods: This cross-sectional study enrolled 34 children (18 girls) who had received GPO-VIR S30 (30 mg stavudine, 150 mg lamivud...
Saved in:
Main Authors: | , , , , , , , |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=25844490364&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/62249 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
id |
th-cmuir.6653943832-62249 |
---|---|
record_format |
dspace |
spelling |
th-cmuir.6653943832-622492018-09-11T09:26:00Z Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine Kulkanya Chokephaibulkit Nottasorn Plipat Tim R. Cressey Koen Frederix Wanatpreeya Phongsamart Edmund Capparelli Teera Kolladarungkri Nirun Vanprapar Immunology and Microbiology Medicine Objective: To evaluate the steady state pharmacokinetics of nevirapine (NVP) in HIV-infected children receiving a fixed-dose combination of stavudine, lamivudine and NVP. Methods: This cross-sectional study enrolled 34 children (18 girls) who had received GPO-VIR S30 (30 mg stavudine, 150 mg lamivudine and 200 mg NVP) for at least 8 weeks. Tablets were divided into quarter fractions (1/4, 1/2, 3/4 or 1 tablet) to attain the NVP dosages of 120-200 mg/m2every 12 h. Plasma NVP levels were measured at predose, and at 2 and 6 h after drug administration. Results: The median age was 8.4 years (range, 3-15). Median CD4 lymphocyte count and percentage at study entry was 576 × 106cells/l and 20.25%, respectively. The median pharmacokinetics parameters were area under the curve at 12 h, 78.4 h × μg/ ml; minimum plasma drug concentration, 5.98 μg/ml; plasma half-life, 25.5 h; apparent oral clearance, 0.079 l/kg per h; and volume of distribution, 2.95 l/kg. Only one child had a minimum plasma drug concentration < 3.4 μg/ml (2.57 μg/ml). Of the 13 children who received GPO-VIR as their first-line regimen, 12 had plasma HIV-1 RNA < 400 copies/ml at 6-18 months, with a median CD4 lymphocyte increase of 216 and 433 × 106cells/l at 6 and 12 months of treatment, respectively. Conclusions: The administration of GPO-VIR S30 fixed-dose combination tablets in fractions or as a whole tablet to children resulted in appropriate NVP exposure and satisfactory virological and immunological benefit. This finding confirms the effectiveness of using a fixed-dose combination as a 'transitional option' while waiting for a paediatric fixed-dose combination drug formulation. © 2005 Lippincott Williams & Wilkins. 2018-09-11T09:24:21Z 2018-09-11T09:24:21Z 2005-09-23 Journal 02699370 2-s2.0-25844490364 10.1097/01.aids.0000183625.97170.59 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=25844490364&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/62249 |
institution |
Chiang Mai University |
building |
Chiang Mai University Library |
country |
Thailand |
collection |
CMU Intellectual Repository |
topic |
Immunology and Microbiology Medicine |
spellingShingle |
Immunology and Microbiology Medicine Kulkanya Chokephaibulkit Nottasorn Plipat Tim R. Cressey Koen Frederix Wanatpreeya Phongsamart Edmund Capparelli Teera Kolladarungkri Nirun Vanprapar Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine |
description |
Objective: To evaluate the steady state pharmacokinetics of nevirapine (NVP) in HIV-infected children receiving a fixed-dose combination of stavudine, lamivudine and NVP. Methods: This cross-sectional study enrolled 34 children (18 girls) who had received GPO-VIR S30 (30 mg stavudine, 150 mg lamivudine and 200 mg NVP) for at least 8 weeks. Tablets were divided into quarter fractions (1/4, 1/2, 3/4 or 1 tablet) to attain the NVP dosages of 120-200 mg/m2every 12 h. Plasma NVP levels were measured at predose, and at 2 and 6 h after drug administration. Results: The median age was 8.4 years (range, 3-15). Median CD4 lymphocyte count and percentage at study entry was 576 × 106cells/l and 20.25%, respectively. The median pharmacokinetics parameters were area under the curve at 12 h, 78.4 h × μg/ ml; minimum plasma drug concentration, 5.98 μg/ml; plasma half-life, 25.5 h; apparent oral clearance, 0.079 l/kg per h; and volume of distribution, 2.95 l/kg. Only one child had a minimum plasma drug concentration < 3.4 μg/ml (2.57 μg/ml). Of the 13 children who received GPO-VIR as their first-line regimen, 12 had plasma HIV-1 RNA < 400 copies/ml at 6-18 months, with a median CD4 lymphocyte increase of 216 and 433 × 106cells/l at 6 and 12 months of treatment, respectively. Conclusions: The administration of GPO-VIR S30 fixed-dose combination tablets in fractions or as a whole tablet to children resulted in appropriate NVP exposure and satisfactory virological and immunological benefit. This finding confirms the effectiveness of using a fixed-dose combination as a 'transitional option' while waiting for a paediatric fixed-dose combination drug formulation. © 2005 Lippincott Williams & Wilkins. |
format |
Journal |
author |
Kulkanya Chokephaibulkit Nottasorn Plipat Tim R. Cressey Koen Frederix Wanatpreeya Phongsamart Edmund Capparelli Teera Kolladarungkri Nirun Vanprapar |
author_facet |
Kulkanya Chokephaibulkit Nottasorn Plipat Tim R. Cressey Koen Frederix Wanatpreeya Phongsamart Edmund Capparelli Teera Kolladarungkri Nirun Vanprapar |
author_sort |
Kulkanya Chokephaibulkit |
title |
Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine |
title_short |
Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine |
title_full |
Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine |
title_fullStr |
Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine |
title_full_unstemmed |
Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine |
title_sort |
pharmacokinetics of nevirapine in hiv-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine |
publishDate |
2018 |
url |
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=25844490364&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/62249 |
_version_ |
1681425771605786624 |